Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

被引:3
|
作者
Riveira-Martin, Mercedes [1 ,2 ]
Struelens, Lara [3 ]
Iglesias, Jose Munoz [4 ]
Schoonjans, Werner [3 ]
Tabuenca, Olga [4 ]
Nogueiras, Jose Manuel [5 ]
Gomez, Francisco Javier Salvador [6 ]
Medina, Antonio Lopez [6 ,7 ]
机构
[1] Galicia Hlth Res Inst IISGS, Genet Oncol Radiobiol & Radiointeract Res Grp, Vigo, Spain
[2] Univ Complutense Madrid, Med Sch, Dept Radiol Rehabil & Physiotherapy, Madrid, Spain
[3] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium
[4] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept SERGAS, Vigo, Spain
[5] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept GALARIA, Vigo, Spain
[6] Univ Hosp Vigo, Meixoeiro Hosp, Med Phys & RP Dept GALARIA, Vigo, Spain
[7] Univ Vigo, Dept Funct Biol & Hlth Sci, Vigo, Spain
关键词
Lu-177]Lu-DOTA-TATE; Occupational exposure; Nuclear medicine; Equivalent dose; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; LU-177; SAFETY; LU-177-DOTATATE; LU-177-OCTREOTATE;
D O I
10.1186/s40658-023-00592-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The use of lutetium-177 (Lu-177)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [Lu-177]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [Lu-177]Lu-DOTA-TATE.Results: A total of 32 administrations of [Lu-177]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 +/- 0.18 mu Sv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 mu Sv/GBq on the non-dominant hand and 45.2 mu Sv/GBq on the dominant hand. For nurses 15.4 mu Sv/GBq on the non-dominant and 13.9 mu Sv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 mu Sv/GBq for physicians and 1.76 mu Sv/GBq for nurses.Conclusions: If appropriate safety measures are taken, the administration of [Lu-177]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.
引用
收藏
页数:25
相关论文
共 39 条
  • [21] Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
    Gadens Zamboni, Camila
    Dundar, Ayca
    Jain, Sanchay
    Kruzer, Marc
    Loeffler, Bradley T.
    Graves, Stephen A.
    Pollard, Janet H.
    Mott, Sarah L.
    Dillon, Joseph S.
    Graham, Michael M.
    Menda, Yusuf
    Shariftabrizi, Ahmad
    EJNMMI REPORTS, 2024, 8 (01)
  • [22] Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE
    Santoro-Fernandes, Victor
    Schott, Brayden
    Deatsch, Ali
    Keigley, Quinton
    Francken, Thomas
    Iyer, Renuka
    Fountzilas, Christos
    Perlman, Scott
    Jeraj, Robert
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (11) : 3428 - 3439
  • [23] Radiation Dose to Medical Staff from Administering 177Lu-PSMA-DKFZ-617 Therapy
    Mahmoudi, Elahe
    Pirayesh, Elahe
    Deevband, Mohammad Reza
    Amoui, Mahasti
    Rad, Mohammadali Ghodsi
    Rad, Mehrdad Ghorbani
    Ghorbani, Mahdi
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 269 - 273
  • [24] Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
    Chicheportiche, Alexandre
    Grozinsky-Glasberg, Simona
    Gross, David J.
    Krausz, Yodphat
    Salmon, Asher
    Meirovitz, Amichay
    Freedman, Nanette
    Godefroy, Jeremy
    EJNMMI PHYSICS, 2018, 5
  • [25] Treatment with tandem [90Y]DOTA-TATE an [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    Seregni, E.
    Maccauro, M.
    Coliva, A.
    Castellani, M. R.
    Bajetta, E.
    Aliberti, G.
    Vellani, C.
    Chiesa, C.
    Martinetti, A.
    Bogni, A.
    Bombardieri, E.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01) : 84 - 91
  • [26] Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
    Prado-Wohlwend, Stefan
    Isabel del Olmo-Garcia, Maria
    Bello-Arques, Pilar
    Francisco Merino-Torres, Juan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset
    Cox, Tony
    O'Connell, Matthew
    Leeuwenkamp, Oscar
    Palimaka, Stefan
    Reed, Nicholas
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (08) : 1305 - 1317
  • [28] Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
    Alexandre Chicheportiche
    Simona Grozinsky-Glasberg
    David J. Gross
    Yodphat Krausz
    Asher Salmon
    Amichay Meirovitz
    Nanette Freedman
    Jeremy Godefroy
    EJNMMI Physics, 5
  • [29] Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
    Zellmer, Johannes
    Yen, Hsi-Yu
    Kaiser, Lena
    Gildehaus, Franz Josef
    Boening, Guido
    Steiger, Katja
    Hacker, Marcus
    Bartenstein, Peter
    Todica, Andrei
    Haug, Alexander R.
    Ilhan, Harun
    BIOMEDICINES, 2022, 10 (12)
  • [30] Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
    Murphy, Ravindhi
    Chander, Gurvin
    Martinez, Maria
    Ward, Caroline
    Khan, Sairah R.
    Naik, Mitesh
    Barwick, Tara
    Aboagye, Eric
    Sharma, Rohini
    BMJ OPEN, 2023, 13 (10):